Drug intelligence / Profile preview

HP3 + HP3.1 + ES19

Development stage
Phase 2
Lead developer
University of Veterinary Medicine, Vienna
Modality
Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
Administration
Intramuscular
01

Overview

HP3 + HP3.1 + ES19 is an experimental trivalent recombinant subunit vaccine candidate designed for the prevention of histomonosis (blackhead disease) in poultry, particularly turkeys and chickens. Developed by researchers at the University of Veterinary Medicine Vienna, the vaccine targets the protozoan parasite *Histomonas meleagridis*. It consists of three recombinant proteins: HP3 and its variant HP3.1, which are putative cell surface proteins identified on the parasite, and ES19, a protein found within the parasite's excretory-secretory products. These antigens were selected based on their immunogenicity and potential to elicit a protective immune response. The vaccine is typically produced using *Escherichia coli* expression systems and is administered via intramuscular injection. Research indicates that the combination of these antigens aims to stimulate both humoral and cellular immunity to reduce the clinical severity and mortality rates associated with *H. meleagridis* infections, which currently lack effective authorized treatments in many regions.

Other names
Histomonas meleagridis subunit vaccineTrivalent Histomonas subunit vaccine
02

Targets

HP3.1 (Histomonas meleagridis cell surface protein HP3.1)ES19 (Histomonas meleagridis excretory-secretory protein ES19)

Beyond the preview

Go deeper on HP3 + HP3.1 + ES19.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on HP3 + HP3.1 + ES19.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call